Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session and finished the day at $0.260. Traded volume was 57,580.00million … Continue reading Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)